Market Snapshot

S&P Futures
4,199.25
Dow Futures
34,469.00
NASDAQ Futures
13,628.25

4.50$-0.56 -11.07%
At close    04:00 PM   
From: To:

Stock Snapshot

5.06
Prev. Close
5.02
Open
84.83M
Market Cap
788,170
Number of Shares
4.2500
Day Low
5.2700
Day High
4.50
-
P/E Ratio
17.93M
Free Float in %
-1.29
EPS 2021
0.80
Book Value per Share
0.14
Cash Flow per Share
Precipio, Inc. (PRPO)
Precipio, Inc. (PRPO) stock rallied over -11.07% intraday to trade at $4.50 per share on NASDAQ. The stock opened with a fall of -0.79% at $5.02 and touched an intraday high of $5.2700, rising 4.15% against the last close of $5.06. The stock went to a low of $4.2500 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-05-06$5.02$4.50$4.50$5.27$4.2514,553,812
2021-05-05$4.87$5.06$5.06$5.75$4.0361,757,700
2021-05-04$6.40$5.25$5.25$9.18$5.05234,235,100
2021-05-03$1.84$4.95$4.95$4.95$1.84333,467,400
2021-04-30$1.86$1.82$1.82$1.93$1.80294,900
2021-04-29$1.98$1.89$1.89$2.05$1.83519,100
2021-04-28$1.90$1.93$1.93$1.98$1.90163,300
2021-04-27$1.91$1.94$1.94$2.00$1.91251,300
2021-04-26$1.90$1.95$1.95$2.05$1.881,090,600
2021-04-23$1.79$1.91$1.91$2.00$1.79496,000
2021-04-22$1.97$1.80$1.80$1.97$1.731,136,200
Precipio, Inc.
4 Science Park
New Haven, CT 06511
United States

http://www.precipiodx.com
203 787 7888
Employees
50
Sector
Healthcare
Sales or Revenue
6.10M
Industry
Diagnostics & Research
5Y Sales Change
25.90
Fiscal Year Ends
2020-12-30
Mr. Ilan Danieli
Founder, Pres, CEO & Director
Mr. Carl R. Iberger
CFO & Sec.
Mr. Ahmed Zaki Sabet
Chief Operating Officer
Precipio, Inc.
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.